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Abstract
Precision medicine requires accurate technologies for drug administration and proper sys-
tems pharmacology approaches for patient data analysis. Here, plasma pharmacokinetics
(PK) data of the OPTILIV trial in which cancer patients received oxaliplatin, 5-fluorouracil
and irinotecan via chronomodulated schedules delivered by an infusion pump into the
hepatic artery were mathematically investigated. A pump-to-patient model was designed in
order to accurately represent the drug solution dynamics from the pump to the patient blood.
It was connected to semi-mechanistic PK models to analyse inter-patient variability in PK
parameters. Large time delays of up to 1h41 between the actual pump start and the time of
drug detection in patient blood was predicted by the model and confirmed by PK data. Sud-
den delivery spike in the patient artery due to glucose rinse after drug administration
accounted for up to 10.7% of the total drug dose. New model-guided delivery profiles were
designed to precisely lead to the drug exposure intended by clinicians. Next, the complete
mathematical framework achieved a very good fit to individual time-concentration PK pro-
files and concluded that inter-subject differences in PK parameters was the lowest for irino-
tecan, intermediate for oxaliplatin and the largest for 5-fluorouracil. Clustering patients
according to their PK parameter values revealed patient subgroups for each drug in which
inter-patient variability was largely decreased compared to that in the total population. This
study provides a complete mathematical framework to optimize drug infusion pumps and
inform on inter-patient PK variability, a step towards precise and personalized cancer
chronotherapy.
Author summary
Accuracy and safety of infusion pumps remain a critical issue in the clinics and the devel-
opment of accurate mathematical models to optimize drug administration though such
devices has a key part to play in the advancement of precision medicine. Here, PK data
from cancer patient receiving irinotecan, oxaliplatin and 5-fluorouracil into the hepatic
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A (2020) Optimizing circadian drug infusion
schedules towards personalized cancer
chronotherapy. PLoS Comput Biol 16(1):
e1007218. https://doi.org/10.1371/journal.
pcbi.1007218
Editor: James Gallo, University at Buffalo - The
State University of New York, UNITED STATES
Received: June 26, 2019
Accepted: November 21, 2019
Published: January 27, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pcbi.1007218
Copyright: © 2020 Hill et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: All model code is
available from a public GitHub repository at https://
github.com/Rogerjwhill/Optimizing-circadian-drug-
infusion..git.
artery via an infusion pump was mathematically investigated. A pump-to-patient model
was designed and revealed significant inconsistencies between intended drug profiles
and actual plasma concentrations. This mathematical model was then used to suggest
improved profiles in order to minimise error and optimise delivery. Physiologically-based
PK models of the three drugs were then linked to the pump-to-patient model. The whole
framework achieved a very good fit to data and allowed quantifying inter-patient variabil-
ity in PK parameters and linking them to potential clinical biomarkers via patient cluster-
ing. The developed methodology improves our understanding of patient-specific drug
pharmacokinetics towards personalized drug administration.
Introduction
Cancer management is challenged by large inter- and intra-patient variabilities in both disease
progression and response to treatments. Thus, the quest for accurate and personalized cancer
therapies has fostered the development of new technologies enabling multi-type measurements
in individual patients and complex drug scheduling. To translate datasets available for an indi-
vidual patient into personalized therapies and further ensure their precise administration, new
mathematical approaches are required. Indeed, systems medicine, that involves the implemen-
tation of theoretical approaches in medical research and practice, is critically needed as
emphasized in the roadmaps of the Coordinated Action for Systems Medicine (CaSyM) from
the European Union (https://www.casym.eu, [1]) and of the Avicenna action (http://avicenna-
isct.org/), and in other international consortia [2–5]. The final aim is a measurable improve-
ment of patient health through systems-based practice which will enable predictive, personal-
ised, participatory and preventive (P4) medicine [6].
Accuracy and safety of infusion pumps are mandatory to ensure that the correct drug
dose is delivered to the patient over the intended period. Recurrent incidents related to
devices delivering fluids such as nutrients or medications into the body have led the U.S
Food and Drug Administration (FDA) to launch in 2010 an initiative to reduce infusion
pump risks (https://www.fda.gov/medicaldevices/productsandmedicalprocedures/
generalhospitaldevicesandsupplies/infusionpumps/ucm202501.htm). Many of the reported
events are related to deficiencies in the initial design of the device and of the embedded soft-
ware. Adverse events may also arise from a defect appearing over the device’s life cycle due
to technical failure or lack of proper maintenance. However, due to the complexity of the
equipment, user errors are also common [7].
Optimizing chemotherapeutics index, defined as the ratio between treatment antitumor
efficacy and induced toxicities, is complex at multiple levels. First, large inter-patient variabili-
ties are demonstrated in drug pharmacokinetics, tolerability and anti-tumour efficacy [2, 8–
10]. Next, important intra-patient variabilities arise from the fact that tumour and healthy tis-
sues, rather than being static over time, display time-dependent variations, in particular over
the 24h span, which are called circadian rhythms [11]. The circadian timing system controls
most physiological functions of the organism resulting in drug Absorption, Distribution,
Metabolism and Elimination (ADME) displaying 24h-rhythms with differences of up to sev-
eral folds between minimum and maximum activities [12, 13].
Chronotherapy -that is administering drugs according to the patient’s biological rhythms
over 24 h- is a growing field in medicine and especially in oncology. Indeed, at least 22 clinical
trials involving a total of 1773 patients with different types of metastatic cancers have demon-
strated a significant influence of administration timing on the tolerability of 11 commonly-used
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antitumor drugs [14]. Two randomized phase III clinical trials in 278 metastatic colorectal can-
cer (mCRC) patients receiving oxaliplatin and 5-fluorouracil showed that cancer chronotherapy
achieved an up-to-5-fold decrease in treatment side effects and nearly doubled anti-tumour effi-
cacy compared to conventional administration of the same drug doses [15]. However, a meta-
analysis of these two studies combined to another clinical trial involving 564 mCRC patients
receiving the same drugs (497 men and 345 women in total) concluded that the chronomodu-
lated drug modality significantly increased the efficacy and survival in men while reducing that
in women as compared to conventional administration [16]. Such sex-specificity was further
validated for irinotecan chronotoxicity in mouse experiments [17] and in a clinical trial involv-
ing 199 mCRC patients treated with oxaliplatin (infusion peak 4pm), 5-fluorouracil (infusion
peak 4am) and irinotecan given at 6 different circadian times [18]. Both studies showed a higher
circadian amplitude in females as compared to males and a difference of several hours between
the optimal timing of each gender. Furthermore, circadian biomarker monitoring in individual
patients recently revealed up to 12 h inter-patient differences regarding the timing of midsleep,
the circadian maximum in skin surface temperature or that in physical activity [19]. These
investigations have highlighted the need for the individualization of drug combinations and
chronoinfusion schemes to further improve treatment outcome, taking into account the
patients’ sex, chronotype and genetic background. The accurate delivery of intended adminis-
tration profiles is obviously critical in this context. Chronotherapy requires the error in drug
infusion timing not to be greater than few hours.
Clinical findings about cancer chronotherapy have motivated the development of innova-
tive technologies for chronomodulated drug delivery including the Mélodie infusion pump
(Axoncable, Montmirail, France, [20]). This portable electronic pump allows for the adminis-
tration of up to 4 compounds according to pre-programmed schedules over the 24 h span. It
was used in several clinical trials for the chronomodulated delivery of irinotecan (CPT11), oxa-
liplatin (L-OHP) and 5-fluorouracil (5-FU) into the central vein of metastatic colorectal cancer
patients [13]. The Mélodie pump was recently used to infuse those three anticancer drugs
directly into the hepatic artery of metastatic cancer patients in the translational European
OPTILIV Study [20]. This uncommon delivery route into the hepatic artery and the use of an
infusion pump to deliver the drugs according to chronomodulated profiles represent a novel
chemotherapeutic approach which needs to be quantitatively investigated to maximize patient
benefit. In this study, the plasma pharmacokinetics of oxaliplatin revealed inconsistencies
between programmed delivery schedules and observed drug concentration within the patient
blood including a delay in the time taken for the drug to be detectable in the blood and unex-
pected peaks in plasma concentrations during drug infusion. Such inconsistencies between
targeted drug exposure patterns and plasma drug levels motivated the design of a mathemati-
cal model of fluid dynamics within the pump system presented hereafter. This pump-to-
patient model was then connected to semi-physiological PK models to investigate the inter-
patient variability in drug PK after hepatic artery administration. Thus, this systems pharma-
cology study aimed to develop predictive mathematical models allowing for the quantitative
and general understanding of i) the pump dynamics, irrespective of the drug delivery device,
and ii) patient-specific whole-body PK of irinotecan, oxaliplatin and 5-fluorouracil after drug
administration using an infusion pump. Such mathematical techniques would then allow for
precise and personalized drug timing.
Results
The overall objective of this study was to accurately investigate the inter-patient variability in
the plasma PK of the three anticancer drugs administered during the OPTILIV trial. A first
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strategy consisted in using compartmental PK modelling taking the delivery profiles pro-
grammed into the infusion pump as inputs for the plasma compartments. However, such
methodology revealed inconsistencies between the best-fit models and the data, including
delays of several hours. We then concluded that the fluid dynamics from the pump to the
patient had to be quantitatively modelled. Hence, we designed the complete model in two
sequential mathematical studies. First, we studied the drug solution dynamics from the pump
to the patient blood for which the model was based on partial differential equations. This novel
model of the pump delivery system took into account the specificity of the equipment used in
order to accurately predict drug delivery in the patients’ blood, although it those can be easily
adapted to any drug delivery devices. Second, we connected this model to compartmental PK
models based on ordinary differential equations. This complete framework allowed for the
investigation of inter-patient variability in drug PK after hepatic artery administration.
Pump-to-patient drug solution dynamics
Model design. The pump-to-patient model is a transport equation representing the
dynamics of the drug solution along the administration tube, with respect to time (t) and one-
dimensional space (x)(Eq 1). x is the distance along the tube from the pump (x = 0) to the
patient (x = L). The drug solution was assumed to be incompressible so that the fluid velocity
was considered as constant along the whole tube. Thus, the drug concentration in the tube u(x,
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where V(t) is the fluid velocity inside the tube, expressed in m/h. The constant sa = πr2 is
the cross sectional surface area of the tube (in m2), with r being the radius of the tube. The
source term S(t) represents the amount of drug delivered according to the infusion profile
programmed into the pump and is expressed in mol/h. Initial conditions along the tube are
u(x, 0) = [0, L]. The fluid velocity and source terms are controlled by the pump which imposes
a fluid delivery rate expressed in ml/h. They are computed by converting the fluid delivery rate
into m/h and mol/h respectively using the tube geometry and the concentration of each drug
solution. Hence, model simulations at the end of the tube (x = L) do not depend on the exact
geometry of the tube but rather on its total volume. The input function for PK models depend-
ing only on quantities at the end of the tube, the original infusion tube which was constituted
of two sections of different diameters was simplified in numerical simulations to a tube of
radius 1mm and total length 2340mm that had the same total volume as the original set-up.
The total tube volume was set to 1.84 mL as in the equipment used in the OPTILIV study. The
transport equation with associated initial and boundary conditions can be solved using the












where τ(x, t) is the time at which the drug reaching point x at time t initially entered the system
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The input function for the PK models corresponds to the rate of drug infusion into the
patient (i.e. at x = L) and can be obtained by:
dðtÞ ¼ sa� VðtÞuðt; LÞ ¼




VðtÞ SðtLðt;LÞÞVðtLðt;LÞÞ otherwise; with
R t




Note that, for all drug infusion apart from the glucose flushes, the source term S(t) is pro-
portional to the fluid velocity V(t) as the drug is infused within the tube in the same time as
the fluid, so that d(t) is proportional to V(t) once the tube is filled i.e. for times t such that
R t
0
VðrÞdr < L. An example of the PDE model simulations in time and space for oxaliplatin
delivery is shown in Fig 1A.
Differences between programmed infusion profiles and actual drug
delivery in the patient’s blood
The pump infusion schemes used in the OPTILIV trial were simulated for the three drugs: iri-
notecan, oxaliplatin and 5-fluorouracil. Whereas the drug profiles programmed into the pump
followed a smooth sinusoidal function, the actual drug delivery in the patient artery differed
from the programmed profiles by two main features. First, the model predicted a significant
time delay between the actual start of the drug delivery by the pump and the time the drug first
reached the patient blood (Fig 1B–1G). This delay was evaluated by the model to 3 h 05 min
for oxaliplatin, 2 h 20 min for 5-fluorouracil and 51 min for irinotecan. It corresponded to the
time taken to fill the infusion tube with the solution containing the drug at the beginning of
the infusion. The delay was drug-specific as it depended on the drug solution concentration
and the velocity of the solution in the tube driven by the programmed input profiles. Next, at
the end of the infusion profiles, the pump stopped and did not administer the amount of drug
left inside the tube. This remaining drug was flushed out by the glucose rinse subsequent to
drug administration which induced a sudden delivery spike in the patient artery (Fig 1B–1G).
The amount of drug in this spike was expressed in percentage of total drug delivered and was
estimated to 10.7% for oxaliplatin, 5.36% for 5-fluorouracil and 1.85% for irinotecan. Doses
and rates can be seen in Table 1.
Our systems approach revealed important differences between the intended drug infusion
profile and the actual administration into the patient artery. Hence, we developed optimized
infusion profiles that strictly achieved the drug administration intended by clinicians. The
same equipment was considered to avoid cost of changing. Drug concentrations of the infu-
sion solutions were kept unchanged in order to avoid possible problems of drug stability. In
order to administer the drug in the patient’s blood following a smooth sinusoidal function, a
profile in three parts is required as follows (Fig 2). The first part of the profile is an initial bolus
to fill the tube between the pump and the patient with the drug solution. Once the tube is filled,
the original sinusoidal profile starts. Then, to solve the problem of the amount of drug left in
the tube when the pump stops, the original sinusoidal profile needs to be interrupted when the
total drug amount has left the drug bag. Then, a subsequent glucose rinse needs to be infused
according to the final segment of the sinusoidal curve in order to deliver the drug remaining
in the tube at the correct rate.
Optimizing circadian drug infusion
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Inter-patient variabilities in irinotecan, 5-fluorouracil and oxaliplatin PK after chrono-
modulated administration. The pump-to-patient model provided educated predictions of
the drug infusion into the patients’ blood, which was a prerequisite to study the inter-patient
variability in the PK of irinotecan, oxaliplatin and 5-fluorouracil. A compartmental
Fig 1. (A) shows oxaliplatin concentration profile in the infusion tube. The x-axis represents the distance along the tube, the y-axis represents the time from the start of
the pump delivery. For figures (B-G), the x-axis represents Clock time and starts at the beginning of the considered drug administration. The left column shows the
difference between the intended delivery profiles and the simulated delivery profiles evaluated at the end of the tube (x = L), for irinotecan (B), oxaliplatin (D) and
5-fluorouracil (F). The right-hand column shows the cumulative percentage of drug delivered to the patient for the intended and actual profiles over time for irinotecan
(C), oxaliplatin (E) and 5-fluorouracil (G).
https://doi.org/10.1371/journal.pcbi.1007218.g001
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physiological model was designed for each drug separately, since interactions between CPT11
and LOHP, and between LOHP and 5-FU have not been demonstrated [22, 23] and CPT11
and 5-FU also showed no interaction if CPT11 is delivered first as it is in this study [24]. All
parameters were fitted for each patient and each drug independently.
Compartmental models of irinotecan, oxaliplatin and 5-fluorouracil
pharmacokinetics
Model design. PK models represented the drug fate in: the Liver, to accurately represent
hepatic delivery, the Blood, the measurement site, and the rest of the body known throughout
this paper as Organs. The volume of each compartment was individualised for each patient
using Vauthey method for Liver [25], Nadler’s formula for Blood [26], and Sendroy method for
Table 1. Table describing the defining delivery values for CPT11, LOHP and 5-FU. The main peak refers to the maximum flow rate from the intended delivery schedule.
The spike peak rate refers to the maximum flow rate of the delivery caused by the glucose flush.
Drug Total dose (mg/m2) Drug solution concentration (mg/ml) Main peak rate (ml/m2/h) Spike peak rate (ml/m2/h)
CPT11 180 3.33 18.02 7.38
LOHP 28 3 1.63 7.28
5-FU 933 50 3.4 6.96
https://doi.org/10.1371/journal.pcbi.1007218.t001
Fig 2. Improved administration profiles. (A) shows the drug solution delivery profile which consists of an initial bolus to fill the tube entirely, followed by the original
profile. (B) shows the rinse solution delivery rate which continues drug delivery at correct rate while clearing the tube from any active substance, Original rinse peaks
were kept unchanged, although there are not mandatory in this administration design. (C) shows how the flow rate along the tube is smoothly switched between the drug
and the rinse and (D) shows the new drug delivery profile that will enter the patient compared to the original profile used in the OPTILIV study.
https://doi.org/10.1371/journal.pcbi.1007218.g002
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Organs [27] (See S1 Text for exact formulas used). Each model assumed that the drug was deliv-
ered directly into the liver compartment to represent the Hepatic Artery Infusion (HAI, Figs 3,
4 & 5). All transports in between compartments were considered as passive and were repre-
sented by linear terms. Throughout this paper, the terms Blood-Liver or Blood-Organ transport
represent a bidirectional transport that encompasses the transfer across the blood vessel walls
into/from tissues. This simplification has been adopted due to lack of data on the transport pro-
cesses between compartments. In the models, the drug clearance terms accounted for all types
of drug metabolism which were not explicitly modelled (e.g. hepatic CYP450 activity) and i)
renal elimination for the Blood compartment, ii) intestinal elimination for the Organs
Fig 3. Semi-physiological model of irinotecan PK. Compartments were minimised to the most important
components, Liver to accurately represent drug delivery, Blood which is measurement site and Organs to represent the
rest of the body. Ci is the rate constant of clearance from compartment i. Irinotecan is bio-activated into its active
metabolite SN38. Irinotecan was assumed to be delivered directly into the liver.
https://doi.org/10.1371/journal.pcbi.1007218.g003
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compartment and iii) biliary excretion for the Liver compartment only for irinotecan and
5-fluorouracil since it could be neglected for oxaliplatin [28–30]. The Organs compartment did
not include the intestinal lumen and only accounted for the intestinal cells composing the wall
of the intestine which were exposed to the drug through blood circulation. The intestinal cells
may expel the drug toward the lumen or transform the drug through metabolism, both phe-
nomena being represented by the intestinal clearance in the models. The drug excreted through
the bile directly reached the intestinal lumen—which was not considered as part of the Organs
compartment- and the drug recirculation was neglected. In the absence of quantitative data and
to avoid model over-parametrization, circadian rhythms were neglected in the PK models and
all parameters were assumed to be constant over the 8-hour time window of PK measurements.
Fig 4. Semi-physiological model of oxaliplatin PK. Compartments were minimised to the most important
components, Liver to accurately represent drug delivery, Blood which is measurement site and Organs to represent the
rest of the body. Ci is the rate constant of clearance from compartment i. Each compartment contains a bound and
unbound drug fraction and only unbound molecules can migrate between compartments. b and u are respectively the
binding and unbinding rate constants of platinum to proteins. Oxaliplatin was assumed to be delivered directly into
the liver in its unbound form.
https://doi.org/10.1371/journal.pcbi.1007218.g004
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Any chemical species bound either to plasma proteins or to DNA was assumed to be unable to
move between compartments or to be cleared from the system.
Parameter identifiability assessed though sensitivity analysis to cost function variations
revealed poor sensitivity of the clearance rate constant in the Organs compartment for the
three drugs (cf. Methods). Hence, Organ clearance was neglected for 5-fluorouracil which is
mainly cleared through hepatic metabolism, biliary excretion and renal elimination [30].
Organs clearance and liver clearance was neglected for oxaliplatin since majority of platinum
is cleared via renal clearance and the total amount cleared after the end of treatment was set to
Fig 5. Semi-physiological model of 5-fluorouracil PK. Compartments were minimised to the most important
components, Liver to accurately represent drug delivery, Blood which is measurement site and Organs to represent the
rest of the body. Ci is the rate constant of clearance from compartment i. 5-fluorouracil was assumed to be delivered
directly into the liver.
https://doi.org/10.1371/journal.pcbi.1007218.g005
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54% in line with the literature [28]. Irinotecan organ clearance was assumed to be scaled rela-
tive to that of the Liver compartment, this is since similar amounts of irinotecan are cleared
via faecal clearance and biliary clearance [29]. In the model of 5-fluorouracil, poor sensitivity
was also obtained for transport parameters between Blood and Organs. Hence, transport rate
constants were assumed to be proportional to compartment volumes for Blood-Liver and
Blood-Organs transport, for each of the three drugs, thus neglecting organ-specific transporter
expression.
Parameter likelihood profiles analysis revealed that additional constraints were needed to
ensure the identifiability of all parameters (see Methods). Hence, information on renal, intesti-
nal and hepatic clearance relative rates was inferred from literature as follows. For irinotecan,
CPT11 drug amount though renal clearance and though combined intestinal elimination and
biliary clearance were respectively set to 25% and 60% of the total administered dose [29]. As
SN38, which is the active metabolite of CPT11, renal elimination was documented as negligi-
ble, the metabolite was considered to only be cleared through Liver, via metabolism into
SN38G, or Organs and these cleared amounts were assumed to account for 15% of the total
administered dose of irinotecan [29]. The amount of SN38 cleared via metabolism in the liver
accounted for approximately 4% of the total administered does of irinotecan whereas SN38
excretion into the intestinal lumen accounted for approximately 9% of the total dose of irinote-
can. Therefore we have set the SN38 clearance via Organs to be twice that of the liver clearance
[29]. Oxaliplatin clearance was set such that 54% of the total administered drug amount was
cleared via the kidneys [28]. The amount of platinum (Pt) bound within the Organs or within
the Liver was set to 84% and 12% of the total dose, respectively [31]. The Boughattas et al
paper was used to give tissue concentrations, no data to our knowledge exists for humans so
we have used this mouse data as a best approximation. The amount of platinum in the tissues
was calculated from total amount found in the respective organs relative to total dose. 5-FU
was shown to be mainly cleared through hepatic metabolism, so that the amount of drug
cleared through the Liver was assumed to account for approximately 80% of the total dose
[30].
The final irinotecan model had six compartments as each of the three Liver, Blood and
Organs, had two sub-compartments: the parent drug irinotecan, and its active metabolite
SN38 (Fig 3). Initial irinotecan administered in the liver was assumed to be only in the form of
the parent drug. Irinotecan was converted into SN38 via Michaelis Menten kinetics within the
liver and organs, but not in the Blood since the activation enzymes carboxylesterases are not
expressed in blood cells in humans [32]. The parameter estimate Km = 59.2μM which reflects
the affinity of the substrate and the enzyme was taken directly from an in vitro study in human
liver cells [33], thus making the assumption that Km values are unchanged from in vitro to in
vivo as classically done in the literature [34, 35]. SN38 was considered to only be present in its
bound form since the bound fraction is reported to be greater than 95% [36]. SN38 clearance
terms accounted for SN38 elimination including its deactivation into SN38G though UDP-gly-
cosyltransferases (UGTs) [37].
The oxaliplatin PK model had six compartments corresponding to bound and free (Pt)
molecules in the Liver, Blood and other Organs. Oxaliplatin is rapidly metabolised into plati-
num complex forms [28], which were not distinguished in the current data. In the absence of
any data on the dynamics of these different metabolites, they were all assumed to have the
same PK properties in the model. Initial oxaliplatin administered in the liver was assumed to
be free. Free Pt could bind to proteins and unbind from proteins, due to protein degradation
[28], which was included in all compartments (Fig 4).
The final model for 5-fluorouracil had three compartments. The drug clearance accounted
for both drug elimination and drug metabolism in each compartment (Fig 5). Protein binding
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of 5-fluorouracil was neglected in the model because of the low protein affinity of this drug
[38]. Equations for the three models can be seen in S1 Text.
Inter-patient variability in irinotecan, oxaliplatin and 5-fluorouracil PK parameters.
Overall, each of the three drug models showed a very good fit to data as demonstrated by R2
values averaged over all patients of 0.98 for irinotecan, 0.96 for oxaliplatin and 0.8 for 5-fluoro-
uracil (Figures A, B and C and table D, G and J in S1 Text). These results obtained using infu-
sion rates computed through the pump-to-patient model were compared with simulations
with infusion rates equal to the profiles programmed into the pump. Using the pump-to-
patient model allowed the improvement of the model fit to pooled data for each drug (Tables
C, D, F, G, I and J S1 Text) and the model fit to patient specific data for SSR values by an aver-
age of 4.9% for irinotecan, 43.4% for oxaliplatin and 12.5% for 5-fluorouracil, thus proving the
validity of our approach. The irinotecan model had an almost perfect fit, it matched the linear
increase of AUC compared to dose as described in the FDA drug label (Figure B in S1 Text)
[39], and showed a rapid accumulation of both irinotecan and SN38 in the plasma of patients
(Fig 6). No obvious impact on irinotecan and SN38 plasma concentrations was observed
regarding the time needed to fill the infusion tube or the 30-min glucose delivery spike, as pre-
dicted by the pump-to-patient model.
The fit for the oxaliplatin PK model captured all general trends (Fig 7). The model fit for
patient 7 did not fully captured the dynamics of total Pt plasma concentration but correctly
simulated free Pt concentration. The model did predict i) a delay in plasma Pt concentrations
at the start of the infusion due to the pump-to-patient drug transport and ii) a spike during the
glucose flush for all patients. This drug spike had an effect on the time of maximum concentra-
tion tmax of the free Pt by shifting the time by up to 6 h. The model underestimated the free
platinum peak concentrations after the glucose flush for the patients with the most significant
rise in concentration, that are patients 2, 3 and 7.
The 5-fluorouracil model showed a very good fit to data, despite a slight systematic under-
estimation of the third data point in time. It predicted the glucose flush to induce a late spike
in plasma drug concentration which could not be seen in the data for all patients, probably
because blood sampling frequency was not high enough (Fig 8). This model-predicted spike in
5-fluorouracil concentration changed the tmax value for Patient 5, 6 and 9. The predicted
spike AUC was equal to approximately 5% of the total AUC which was in agreement with the
pump-to-patient model prediction. This was only calculable for 5-fluorouracil since its elimi-
nation was fast enough for its concentration to be close to zero by the time the glucose flush
began.
The model fit to each individual patient PK data allowed to investigate the inter-patient var-
iability in resulting PK parameters (Fig 9A, 9B and 9C). The CV of each PK parameter was cal-
culated among the patient population (Table A, E and H in S1 Text). Then, the mean CVs for
the entire parameter set of each drug model were calculated as a single measure of inter-patient
variability. Irinotecan had the smallest mean CV with a value of 79.18%, and a range from
42.48 to 176.25%. Oxaliplatin had the second smallest value of mean CV, 97.56%, with the larg-
est range from 38.1–318.2%. 5-fluorouracil had the largest mean CV at 112.10%, with the
smallest range from 59.4 to 187.51%. In all three models the parameters which showed the
largest inter-patient variability were transport parameters specifically, for irinotecan Blood-
Organ transport, for oxaliplatin Blood-Liver Transport and Blood-Liver/Organ transport for
5-fluorouracil.
For each drug model, individual patient parameter sets were then utilized to identify patient
clusters. The numbers of clusters were determined by minimising the validity index of Fuku-
yama and Sugeno VFS as described in [40]. Clustering for different numbers of clusters and
their respective VFS can be seen in the S1 Text (Figures G, H and I in S1 Text). For irinotecan,
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Fig 6. Patient data best-fit of irinotecan PK model. Each subplot represents an individual patient dataset, fit to the model
independently. (A) shows the fit of irinotecan plasma concentration, (B) shows that of SN38, the active metabolite of irinotecan.
https://doi.org/10.1371/journal.pcbi.1007218.g006
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Fig 7. Patient data best-fit of oxaliplatin PK model. Each subplot is an individual patient data, fit to the model independently. (A) shows
plasma ultrafiltrate platinum concentrations, and (B) shows plasma total platinum concentrations. PK data for Patient 11 was missing.
https://doi.org/10.1371/journal.pcbi.1007218.g007
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the minimum value of VFS was achieved for four clusters. One cluster was composed of
Patients 1, 2, 3, 5, 7, 8, 9 and 10, the other three patients were in a cluster on their own. The
analysis for oxaliplatin concluded to two clusters, a cluster of only one patient, patient 7, and
the rest of the patients being clustered together. The analysis for 5-fluorouracil revealed four
clusters: 5 patients were grouped in the largest cluster (Patients 1, 2, 3, 7, and 10), two patients
in the second cluster (Patients 4, 5) and the final two patients were in clusters on their own.
Only patients 1, 3 and 10 were consistently clustered together for all three drugs. Once the
patient PK parameters had been clustered, the mean of parameter CVs was reassessed for each
cluster with 2 or more patients within. Irinotecan mean CV in the largest cluster was 51.52%,
which represented a large decrease compared to the mean CV in the entire patient population
equal to 79.18%. Oxaliplatin main cluster which was constituted of all patient but patient 7 had
a mean CV of 87.37% as compared to 97.56% for the entire population. 5-fluorouracil’s largest
cluster had a CV of 32.37% and the smaller cluster had a CV of 72.87%, which corresponded
to a drastic decrease of inter-patient variability as the population mean CV was equal to
112.10%. All other clusters for each drug had only a single patient and therefore the CV could
not be assessed. Clustering was compared to covariates of patients, such as gender, age and
gene polymorphism, to see if there was any correlation however none was found.
Discussion
Precision and personalized medicine requires accurate technologies for drug administration
and proper systems pharmacology approaches for individual patient multidimensional data
Fig 8. Patient data best-fit of 5-fluorouracil PK model. Each subplot is an individual patient data fit to the model
independently. PK data for Patient 6 and 11 was missing.
https://doi.org/10.1371/journal.pcbi.1007218.g008
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Fig 9. Inter-patient variability in drug PK parameters. The first line shows parameter variability across the considered patient population for irinotecan (A),
oxaliplatin (B) and 5-fluorouracil (C), the colour and symbols represent the clusters each parameter set belongs to. The parameters are named with reference to the
schematics of the models, the subscripts refer to the blood (B), organs (O) and liver (L). In the irinotecan parameters, additional subscripts cpt and sn refer to irinotecan
and SN38 respectively. The second line shows multidimensional scaling representation of patient clustering based on their PK parameters for irinotecan (D), oxaliplatin
(E) and 5-fluorouracil (F), the x refer to the cluster centroids and the points refer to patient PK parameters projected onto 2D plot.
https://doi.org/10.1371/journal.pcbi.1007218.g009
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analysis. Here, plasma PK data of the OPTILIV trial in which patients received irinotecan, oxa-
liplatin and 5-fluorouracil through a chronomodulated schedule delivered by an infusion
pump into the hepatic artery were mathematically analysed. To allow for an accurate analysis
of PK patient data, a model of the pump drug delivery was successfully designed and con-
nected to semi-mechanistic PK models. Although no data were available to directly validate
the model-predicted drug infusion rates, the overall framework achieved a very good fit to
individual time-concentration profiles which showed model accuracy. The validity of the
approach was further demonstrated by the improved data fit using the PDE explicit solution
connected to PK models compared to PK models directly integrating infusion profiles that
were programmed into the pump. This study gave insights into inter-patient variability and
paved the path to treatment optimization.
The simulations for the pump-to-patient model showed and quantified a delay between the
actual start of the pump and the time when the drug appeared in the patient blood which was
due to the delay needed for the drug solution to fill up the infusion tube and eventually reach
the patient. A validation of this model prediction could be seen directly in the data as 5-fluoro-
uracil and oxaliplatin plasma concentrations were close to zero for the first two times of mea-
surements. The length of this delay depends on both the drug solution concentration and the
volume of the infusion tube, so that its importance was high for oxaliplatin, intermediate for
5-fluorouracil and minor for irinotecan. Temporal accuracy is key for precision medicine
especially in the context of chronotherapy and chronomodulated drug delivery. Thus, the pro-
grammation of any drug administration devices need to account for these delays. The pump-
to-patient model that we present here allow to adapt any infusion schemes for any drug
administration devices in order to properly administer the treatment schedules initially
intended by the oncologists.
In addition to such “pump-to-body” delay, the increase in free Pt concentration near 22:00
shown in the PK data was explained by a spike in oxaliplatin delivery resulting from the glu-
cose rinse flushing out the residual oxaliplatin left within the infusion tube. This phenomenon
was well captured and quantified by oxaliplatin PK model which predicted that the quantity of
drug delivered in the final spike was equal to 10.7% of the total dose. The model also showed
that the tmax of oxaliplatin plasma concentration was shifted by several hours due to this deliv-
ery profile spike. In silico simulations also predicted that the glucose flush would alter the PK
of 5-fluorouracil. The spike only accounted for a small amount of 5-fluorouracil dose of 5.36%
and may not have caused any significant detrimental effect. More data points covering the
time of unexpected drug administration due to the glucose flush would have further validated
the model which already achieved a very good fit to available data points. However, free oxali-
platin plasma concentration displayed complex patterns with high values at the start of the glu-
cose flush for patient 1, 2, 3 and 7 which left no doubt on the large impact of the glucose flush
on oxaliplatin administration. Similarly, unexpectedly high plasma concentrations of 5-fluoro-
uracil were observed at the start of the glucose flush for patient 5 and 9 which partially vali-
dated the model. The delivery spike due to the glucose rinse did not seem to have influenced
the plasma concentration profile of irinotecan because the drug concentration in the solution
was much lower and the flow rate programmed into the pump was much higher as compared
to oxaliplatin and 5-fluorouracil administration. Indeed, the spike only accounted for less than
2% of the total dose of irinotecan.
The pump-to-patient model further showed that these inconsistencies between the simu-
lated and intended drug administration could be overcome with a simple and easily con-
structed adaptation of the infusion profiles, given the specific dimensions of the infusion tube.
The new profile showed a much better match with the original intended administration
profile.
Optimizing circadian drug infusion
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007218 January 27, 2020 17 / 26
Several published clinical studies propose mathematical models of the PK of 5-fluorouracil,
oxaliplatin or irinotecan with various levels of complexity. First, a physiologically-based PK
model of capecitabine, a pro-drug of 5-fluorouracil, was designed for humans [35]. However,
the data available in the OPTILIV study would not allow for estimating parameters of such a
detailed model. Next, numerous clinical studies have performed compartment analysis of
plasma PK data from cancer patients receiving either 5-fluorouracil, oxaliplatin or irinotecan
[41]. These models were designed for intravenous injection and could not be readily used for
intra-arterial hepatic administration. Thus, the development of new semi-physiological PK
models was necessary to include the drug delivery site as a separate compartment, that was dif-
ferent from the Blood compartment for which data was provided. Furthermore, the intention
was also to develop more physiologically-relevant models in view of future account of circa-
dian rhythms and chronotherapy optimization investigations. Indeed, the developed models
are called semi-physiological as the compartment volumes together with relative fractions of
clearance routes were inferred from literature. The quantity of data available for this study lim-
ited the models to being semi-physiological in nature. However, these models could be further
extended to physiologically-based models, with increased data sets, by detailing the“Organ”
compartment and being connected to mechanistic PD models to represent organ-specific drug
PK-PD. Furthermore, the current models do not account for any circadian rhythms although
they may largely impact on drug PK-PD. Thus, new circadian clinical studies are needed to
improve the models towards drug chrono-administration optimization.
Inter-patient differences in maximum plasma drug concentrations and in the time at which
it occurred led us to further investigate variability in between subjects. Irinotecan showed the
lowest mean variability. Clustering analysis indicated that patients could be classified into five
clusters with respect to irinotecan PK parameters. The second largest inter-patient variability
was found for 5-fluorouracil. Clustering for 5-fluorouracil showed there was four clusters.
Regarding oxaliplatin, there was the largest variability between patients PK model parameters
with all parameters showing high variance. Clustering according to oxaliplatin PK parameters
split patients into two clusters leading to isolate patient 7. This clustering of the patients led to
a reduced inter-patient variability for all drugs, especially for irinotecan and 5-fluorouracil.
This decrease in CVs is not unexpected, but the significant level of reduction means this
method could be used as a way to stratify patients into treatment groups with less inter-patient
variability in PK profiles. The measure of inter-patient variability could be interpreted as indi-
cators of the need for personalisation as high differences between subjects implies high poten-
tial benefit of drug administration personalisation. Here, we demonstrated that the PK of all
three considered drugs displayed important inter-subject variability. The remaining clinical
challenge lays in determining clinical biomarkers for stratifying patients before drug adminis-
tration, in order to reach the intended plasma PK levels. In order to do so, patient clusters
were compared to known covariates such as age, gender and gene polymorphisms. However,
none showed significant correlation. We then performed modelling analyses and identified
the critical PK parameters for irinotecan, 5-fluorouracil and oxaliplatin which were the trans-
port parameters between the Blood and either the Liver or the Organs compartments.
Conclusion
In conclusion, a mathematical framework was designed to allow for accurate analysis of patient
PK data. A model of the dynamics of the drug solution from the pump to the patient’s blood
was designed, irrespective of the drug delivery device. It was used to represent the chronomo-
dulated drug administration though the Mélodie infusion pump into the patient hepatic artery
of irinotecan, oxaliplatin and 5-fluorouracil. The model revealed significant inconsistencies
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between the drug profiles programmed into the pump which corresponded to the drug expo-
sure intended by clinicians and the actual plasma PK levels. Importantly, it allowed for the
design of innovative drug in-fusion profiles to be programmed into the pump to precisely
achieve the desired drug delivery into the patient’s blood. Next, the pump-to-patient model
was connected to semi-physiological models of the PK of irinotecan, oxaliplatin and 5-fluoro-
uracil. The overall framework achieved a very good fit to data and gave insights into inter-
patient variability in the PK of each drug. Potential clinical biomarkers for treatment persona-
lisation were suggested although further investigations in larger cohorts of patients are
required. Overall, this complete framework informs on drug delivery dynamics and patient-
specific PK of irinotecan, oxaliplatin and 5-fluorouracil towards precise and personalized
administration of these drugs.
Methods
Ethics statement
The pharmacokinetics data used in this investigation came from Lévi et al pharmacokinetic
investigation [20] and the comparison study companion study of the European OPTILIV trial
(ClinicalTrials.gov study ID NCT00852228), which involved nine centres in four countries
[42]. The data has been analysed anonymously.
OPTILIV clinical datasets
The OPTILIV trial included 11 colorectal cancer patients with liver metastases (7 men and 4
women with median age of 60). The combination of irinotecan, oxaliplatin and 5-fluorouracil
was delivered to patients by Hepatic Artery Infusion (HAI) using the Mélodie pump [20]. The
patients received an intravenous administration of cetuximab 500 mg/m2 over 2 h 30 min on
the morning of day 1 which was not modelled. From day 2, chronomodulated HAI of irinote-
can (180 mg/m2), oxaliplatin (85 mg/m2) and 5-fluorouracil (2800 mg/m2) were given (Fig
10). Irinotecan was delivered as a 6-h sinusoidal infusion starting at 02:00, with a peak at 05:00
on day 2. Oxaliplatin was administered as an 11h 30min sinusoidal infusion beginning at 10:15
with a peak at 16:00 on days 2, 3 and 4. 5-fluorouracil was also delivered as an 11h 30min sinu-
soidal infusion beginning at 22:15 with peak delivery at 04:00 at night, on days 3, 4 and 5. The
superiority of this drug scheduling compared to non-circadian based administration was dem-
onstrated for intravenous administration within several international clinical trials [37].
Between each drug infusion, there was a glucose serum flush which cleared the tubing. This
was a 30-min sinusoidal infusion beginning at 09:45, and then again at 21:45 i.e. at the end of
each infusion (Fig 10).
Plasma pharmacokinetics (PK) data was gathered after the first dose of irinotecan, oxalipla-
tin and 5-fluorouracil and measured longitudinally for each individual patient. Plasma concen-
trations of irinotecan and its active metabolite SN38 were determined, using high performance
liquid chromotagraphy (HPLC), at the start of infusion, then at 2, 3, 4, 6, 8 h 15 min and 31 h
45 min post HAI onset, for a total of seven time points, including baseline. Oxaliplatin concen-
trations were determined by measuring platinum plasma levels using spectrophotometry, for
both unbound and total platinum levels. Oxaliplatin binds to proteins in the blood and the free
Pt fraction is the biologically active one. Thus, oxaliplatin concentrations were determined at
the start time of infusion, then at 3, 6, 9 h, 11 h 30 min and 17 h 15 min post HAI onset, for
a total of six time points, including baseline. Plasma concentrations of 5-fluorouracil were
determined using HPLC, at the start of infusion, then at approximately 3 h, 5 h 45 min, 9 h
and 11 h 30 min post HAI, for a total of five time points, including baseline. The exact
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method used to assess plasma concentrations can be seen in Levi et al paper of the OPTILIV
study [20].
Pump description
The Mélodie pump system weighs 500 g when empty (excluding drug reservoirs and batteries)
and measures 160 x 98 x 34 mm. The pump consists of four channels which correspond to the
four reservoirs that are connected to the pump. Each reservoir can have a maximum volume of
Fig 10. (A) Delivery profiles of irinotecan, oxaliplatin, 5-fluorouracil and glucose flushes as administered in the OPTILIV clinical trial. (B) Schematic of the
Mélodie infusion pump (Axoncable, Montmirail, France) used in the OPTILIV study for hepatic artery infusion [20].
https://doi.org/10.1371/journal.pcbi.1007218.g010
Optimizing circadian drug infusion
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007218 January 27, 2020 20 / 26
2 L. The four channels are controlled by four independent mechanisms which control the
delivery to the infusion tube (Fig 1). For the OPTILIV study, the infusion tube comprised of
two sections, the first was 135mm long with a diameter of 2.5mm, and the second section was
1500mm long with a diameter of 1mm. The two sections had a total volume of 1.84ml. The
four pump reservoirs were loaded with irinotecan, oxaliplatin, 5-fluorouracil and 5% glucose
solution respectively, with the latter one being used for washes in between drug infusions [43].
Mathematical modelling
A pump-to-patient mathematical model was designed as follows, irrespective of the drug deliv-
ery device. The drug solutions dynamics from the pump to the patient’s blood was modelled
using a Partial Differential Equation (PDE) considering time and 1 spatial dimension. This
method was chosen as PDEs can take into account both time and space which was key for
modelling systems such as pump delivery. The PDE was solved using a backward finite differ-
ence method written by the authors within Python 3.5.2 (https://www.python.org/). The drug
PK models were based on Ordinary Differential Equations (ODEs) programmed using Python
3.5.2 and solved using the odeint function from the scipy library version ‘1.1.0’ [44].
PK model parameter estimation involved a weighted least square approach, with conditions
also placed on the drug clearance routes. For the fit of the data of a given patient, the residuals
were weighted by a estimated measurement error of 10% inline with precision values of the
assay methods [45–47]. This method allowed to correct the residuals to be of the same order of
magnitude for the parent drug CPT11 and the metabolite SN38, or for oxaliplatin free and
bound concentrations. The minimization of the least square cost function was performed by
the Covariance Matrix adaptation Evolution Strategy (CMAES) within Python which has been
shown to be successful at handling complex cost function landscapes [48]. Model goodness of
fit was assessed using the sum of squared residuals (SSR) and R2 values. PK model parameter
numerical identifiability given the available data was investigated in a two-step process as fol-
lows. First, parameter sensitivity regarding the least-square cost function was computed via a
global Sobol sensitivity analysis as a necessary condition for identifiability [49]. This method
assesses the relative contributions of each parameter to the variance in the cost function
obtained when parameter values are varied, and thus allows for the identification of parame-
ters which have no effect on the cost function and are therefore not identifiable from the avail-
able dataset. This step allowed a first reduction of the PK models. Next, likelihood profiles of
parameters of the reduced models were derived following the procedure outlined in [50].
Additional biological constraints derived from literature were added to ensure numerical iden-
tifiability of all parameters. This two-step model design process was undertaken as computing
likelihood profiles is associated with a high computational cost.
PK models were fit to pooled data first to get an indication of general model fit then to sin-
gle-patient plasma PK datasets independently to obtain patient-specific parameter values. Data
was available for 10 to 11 patients which was too few to undertake mixed-effect population
analysis and to reliably estimate the parameters variance within a patient population [51, 52].
Sampling points at 6 hours post injection for irinotecan and 11 hours 30 mins post injection
for oxaliplatin and 5-fluorouracil theoretically occurred at the same time as the start of the 30
min glucose flush, that is 9:45 for irinotecan and 5-fluorouracil, and 21:45 for oxaliplatin. As
described in the results section, the flush was equivalent to the administration of the drug
quantity remaining within the tube and logically influenced plasma drug concentrations.
However, the exact time of patient blood collection was not reported and could vary by 10 to
15 minutes due to clinical constraints. Hence, the information of whether the blood sample
was taken before or during the flush was not available. Thus, the collection time of the data
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points at theoretically 21:45 for oxaliplatin, 9:45 for irinotecan and 9:45 for 5-fluorouracil were
unchanged if the drug concentration at the preceding data point was greater than the current
one, indicating the flush might not have occurred yet. If not, the collection time was modified
and set equal to the glucose peak time, which is 15min after its start time i.e. 22:00 for oxalipla-
tin and 10:00 for irinotecan and 5-fluorouracil, such value leading to the best model fit. Over-
all, the collection time was changed compared to the theoretical one for patients 1, 2, 3 and 7
for oxaliplatin, for patient 5 for 5-fluorouracil, and for no patients for irinotecan.
Inter-patient variability and patient clustering based on PK parameters
Given the relatively small number of patients, the inter-patient variability in parameter values









where μ is the parameter mean, σ the parameter sample standard deviation and n is the num-
ber of patients.
Next, fuzzy c-means clustering was used to define patient clusters based on individual PK
parameters, for each drug separately. The fuzzy c-means clustering was done using a python
library sckit-fuzzy version ‘0.2’ (http://pythonhosted.org/scikit-fuzzy/). The method is based
on the determination of cluster centroids and classification of patient parameter vectors into







where n is the number of patients, c is the number of clusters, xi is the parameter vector of
patient i, cj is the centroid of cluster j. wij is the probability of patient i belonging to cluster j












The validity function proposed by Fukuyama and Sugeno was used to determine the num-
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where �c is the average of the centroids. The number of clusters were chosen between 2 and n-1
inclusively such that the VFS was minimised. Plotting the clustering results was done using a
multidimensional scaling (MDS) algorithm which projects multidimensional data onto a 2D
plane while keeping distance metric scaled relatively to original data (Python library sklearn.
manifold [53]). Correlation coefficients between original Euclidean distance and 2D-Euclidean
distance were calculated were high for all models (> 0.98) which showed that the MDS projec-
tions were accurate [54].
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16. Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, et al. Sex moderates circa-
dian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis.
Annals of Oncology. 2012; 23(12):3110–3116. https://doi.org/10.1093/annonc/mds148 PMID:
22745214
17. Li XM, Mohammad-Djafari A, Dumitru M, Dulong S, Filipski E, Siffroi-Fernandez S, et al. A circadian
clock transcription model for the personalization of cancer chronotherapy. Cancer Research. 2013;
73(24):7176–7188. https://doi.org/10.1158/0008-5472.CAN-13-1528 PMID: 24154875
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